89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical ...
NBC Los Angeles1d
Will 2025 finally mark the end of the IPO drought?
Nasdaq president Nelson Griggs discusses the decline of companies going public and when the incentive for initial public ...
JD Supra5d
Public Investment in US Professional Sports: Opportunities and Challenges
The financial landscape of United States professional sports is rapidly evolving. Soaring team valuations, lucrative media rights deals, ...
89bio seeks $250 million in public stock offering
SAN FRANCISCO - 89bio, Inc. (NASDAQ:ETNB), a biopharmaceutical company specializing in liver and cardiometabolic diseases with a current market capitalization of $1.05 billion, has initiated a public ...